.png?sfvrsn=e0d8363_1)
| 1ST APCC CONFERENCE SPEAKERS 2026 | |
 Prof Doris Young | Prof Young is the inaugural Head of the Department of Family Medicine at NUHS. She has extensive experience in educating and training medical students, residents, general practitioners, and other health professionals in adolescent medicine, general practice, and primary care research. Her research focuses on trialling innovative models of care in the primary care setting to improve health outcomes for people with chronic diseases, particularly diabetes mellitus. |
 A/Prof Sarah Bailey Visiting Professor, Dept of Family Medicine, Yong Loo Lin School of Medicine, National University of Singapore (NUS) | Prof Sarah is an academic working at the interface of primary care, cancer epidemiology, and health systems, with a focus on improving early cancer detection in real-world practice. Her work centres on identifying and translating clinically actionable signals of cancer risk - particularly using electronic health record data - and ensuring these insight meaningfully influence clinical decision making, policy, and patient outcomes. A core theme to her programme of work is bridging the gap between evidence generation and implementation. She has experience of leading multi-disciplinary research teams, mentoring early- and mid-career colleagues, and working in close partnership with the UK National Health Service, commercial partners, and community groups. Alongside her academic work, she is actively engaged in international collaboration, public and professional education, and translational initiatives aimed at bringing research into practice at scale. Her long term ambition is to build sustainable, globally relevant programmes of work in early cancer detection that combine scientific rigour, clinical relevance, and societal impact. |
 A/Prof Julia Steinberg Team Lead, Genomics and Precision Health, Daffodil Centre, University of Sydney and Cancer Council NSW | Associate Professor Julia Steinberg is a Cancer Institute NSW Career Development Fellow and leads the Genomics and Precision Health stream of research. Her research programme aims to integrate individual and population-level genomic, sociodemographic, medical, and behaviour information for successful precision health. A/Prof. Steinberg’s focus is on effectively and sustainably improving human health and reducing the burden of cancer. Since completing her DPhil (PhD) in Genomic Medicine and Statistics at the University of Oxford, Julia has gained extensive experience in genetics and genomics. She co-leads the Australian Cancer Risk Study, a collaborative transdisciplinary program on genomic risk prediction and risk-based screening and early detection for the four most common cancers in Australia, funded by the Medical Research Future Fund (MRFF). Julia also leads MCD Spotlight, a new MRFF-funded collaborative research program on the potential of innovative multi-cancer detection (MCD) tests in Australia. This work brings together researchers across many Australian and international institutions, health professionals, and consumers. It aims to establish evidence-based recommendations to help maximise the potential of MCD tests for patient-friendly, more effective and earlier detection of cancers. Another key research area focuses on informing health system requirements for targeted cancer treatment, by estimating the future cancer burden relevant to specific pan-tumour biomarkers (MSI-H/dMMR and NTRK gene fusions). To help integrate genomics into clinical practice, Julia is involved in multiple implementation studies and trials in Australia. Finally, she uses large-scale data to help understand the current patterns and gaps in health care, identifying potential inequities and opportunities for tailored interventions to improve health outcomes. |
 Adj A/Prof Samuel Ow Senior Consultant, Dept of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS) |
Adj A/Prof Samuel Ow is Senior Consultant Medical Oncologist at the Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS). He obtained his medical degree from the Yong Loo Lin School of Medicine, National University of Singapore, where he was awarded Distinction in Medicine, the Nestle Gold Medal, and placed on the Dean's List for his academic achievements. He received the Dean's Award for Outstanding House Officer of his entire cohort, and obtained the Masters of Medicine (Internal Medicine) and Membership of the Royal College of Physicians (UK) on an MOHH Postgraduate Exam Scholarship. He subsequently successfully completed his specialty training in Internal Medicine and Medical Oncology at NCIS where he served as Chief Registrar and was also selected for the inaugural Singapore Chief Residency Program. Adj A/Prof Samuel Ow's clinical and research interests are in Breast Cancer and Clinical Cancer Genetics. He received a Master of Public Heath with concentration in Epidemiology and Biostatistics from the Johns Hopkins Bloomberg School of Public Health on an Academic Medicine Development Award. He is principal / co-investigator in multiple investigator-initiated and international clinical trials and has published his research in peer-reviewed journals. He is an alumnus of the Clinical Cancer Genetics Community of Practice Intensive Course in Cancer Risk Assessment conducted by the City of Hope Comprehensive Cancer Centre, and currently runs the Cancer Genetics Clinic at NCIS. In addition to his clinical work, Adj A/Prof Samuel Ow leads the National Shared Care Initiative for Cancer Survivorship across all three healthcare clusters, which aims to transit the care of cancer survivors to the community. He is a strong advocate in improving access to care and support for cancer survivors and serves as a Council Member of the Singapore Cancer Society. He also sits on the committee for the National Breast Cancer Awareness Month Campaign to help drive greater awareness for breast cancer screening and prevention in the general public. Adj A/Prof Samuel Ow strongly believes in the importance of training the next generation of physicians and was previously Associate Program Director of the Medical Oncology Senior Residency Program at NCIS. He is an Adjunct Associate Professor on the Clinician-Educator track at the Yong Loo Lin School of Medicine, and currently sits in the national Residency Advisory Committee for Medical Oncology. He is active in medical education at the undergraduate and postgraduate level and has been awarded for teaching excellence. On the administrative front, Adj A/Prof Samuel Ow serves as Clinical Director of the Department of Haematology-Oncology and is involved in improving processes to enhance clinical care in cancer patients. He is an advocate for multidisciplinary collaboration, and notably led a team from NCIS to win the Best Practice Medal (Care Redesign Category) at the National Healthcare Innovation and Productivity Medals. |
 A/Prof Jo-Anne Associate Professor, Primary Care and Family Medicine, Lee Kong Chian School of Medicine, NTU and NHG Polyclinics | A/Prof Jo-Anne Manski-Nankervis is an Associate Professor at the Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, and a Principal Clinician Scientist at NHG Polyclinics. She is Academic Director of Primary Care and Family Medicine, Faculty lead of Office of Patient Engagement and Deputy Director, Asian Centre for Health Behavioural Insights & Interventions (HABITS). With a background as an academic general practitioner, her work focuses on advancing primary care, population health, and the integration of research into practice. Her research spans implementation science, digital health, patient and public involvement, and precision prevention, with a strong emphasis on behavioural approaches to improve health outcomes. She leads and contributes to major multidisciplinary programmes in areas including cancer screening, antimicrobial stewardship, patient and public involvement and the adoption of clinical decision support systems in primary care. Dr Manski-Nankervis maintains strong international collaborations, particularly with the University of Melbourne, where she holds a Professorial Fellow appointment. She is passionate about co-design, capacity building, and mentoring early-career researchers, and is committed to translating research into meaningful improvements in care for people and communities. |
 Dr Alicia Ong Associate Consultant , Family Physician, National University Polyclinics | Dr Ong graduated from Duke-NUS Medical School in 2017, and was conferred with the Masters in Family Medicine, NUS, in 2022. She currently practises at Bukit Batok Polyclinic and is involved in undergraduate teaching and research with the NUS Yong Loo Lin School of Medicine. She is interested in research on improving healthcare delivery systems and in promoting chronic disease management. |
 Dr Soon Yu Yang Consultant, Dept of Radiation Oncology, National University Cancer Institute, Singapore (NCIS) | Dr Soon is a radiation oncologist who specialises in thoracic and lower gastrointestinal malignancies. After undergoing radiation oncology training at the National University Cancer Institute, Singapore and Peter MacCallum Cancer Centre, Australia, he was awarded the Thomas Baker Fellowship from the Royal Australian New Zealand College of Radiologists to pursue a Masters of Science in Clinical Epidemiology at the Harvard University. His research is focused on improving health outcomes for those affected by cancer using contemporary clinical trials and evidence synthesis methodologies. He was awarded the NMRC Research Training Fellowship to pursue a PhD in clinical trial methodology at the NHMRC Clinical Trial Centre at the University of Sydney in 2022. He is a Deputy Chair of the lung working party for the Trans Tasman Radiation Oncology Group, and serves as the Co-Chair of OUTRUN, an international randomised trial evaluating the role of stereotactic radiosurgery in EGFR mutant non-small cell lung cancer with brain metastases treated with Osimertinib. He is the faculty of the Australia and Asia Pacific Oncology Research Development Workshop that teaches early career cancer researchers on developing a clinical trial protocol. |
 Prof Martin C.S. Wong | Professor Wong is a scholar and specialist in Family Medicine, and a researcher in the field of cancer screening and prevention of chronic diseases. He is currently a Professor and Director of the Centre for Health Education and Health Promotion, Faculty of Medicine, the Chinese University of Hong Kong. He is also the Associate Head and Dean of Students of the United College, CUHK. He has over 600 publications in international peer-reviewed journals, and has received over 15 international and local research awards for his studies. His expertise of “Colorectal Neoplasm”, “Mass Screening”, “Early Detection of Cancer” ranks in the top 0.055%, 0.095%, and 0.14% in the world, respectively. He ranks as the top number 1 researcher in China in the field of disease screening [from expertscape: https://www.expertscape.com/; on 10/9/2022]. He is a leader of an international research group which is a global organization jointly participated by various Universities in the world. He has been co-chairman of the APRU Global Programme [NCD] for many years. In 2024, he was selected as a “Highly Cited Researcher” by Clarivate, an award which recognizes awardees as the pioneer in his field over the last decade, demonstrating significant and broad influence in one’s field of research. |
 Assistant Professor G. Owen Schaefer | Dr. G. Owen Schaefer was appointed Assistant Professor at the Centre for Biomedical EthiDr. G. Owen Schaefer was appointed Assistant Professor at the Centre for Biomedical Ethics in 2020. He is currently Director of the Phase II Health ethics, Law and Professionalism (HeLP) curriculum. Owen’s research interests cover ethical issues raised by the development of novel biotechnologies. Before beginning his graduate work, Owen spent two years at the Department of Bioethics at the National Institutes of Health in the US as a pre-doctoral fellow. There, he received training in research ethics, was involved in the department’s ethics consultation service, and published several academic articles. He then went on to read for BPhil and DPhil degrees in philosophy at Oxford, writing a dissertation on moral enhancement. Immediately prior to joining the CBmE, he spent a year as a post-doc at the Oxford Centre for Neuroethics researching the implications of various novel biotechnologies. Owen joined CBmE in August 2015 under the MOH-funded initiative, Clinical Ethics Network + Research Ethics Support (CENTRES). In January 2018 he switched roles to be a Research Assistant Professor under the Science, Health And Policy-Relevant Ethics in Singapore (SHAPES) initiative at CBmE, funded by a grant from the NMRC, before taking up his present role as Assistant Professor in July 2020.cs in 2020. He is currently Director of the Phase II Health ethics, Law and Professionalism (HeLP) curriculum. Owen’s research interests cover ethical issues raised by the development of novel biotechnologies. Before beginning his graduate work, Owen spent two years at the Department of Bioethics at the National Institutes of Health in the US as a pre-doctoral fellow. There, he received training in research ethics, was involved in the department’s ethics consultation service, and published several academic articles. He then went on to read for BPhil and DPhil degrees in philosophy at Oxford, writing a dissertation on moral enhancement. Immediately prior to joining the CBmE, he spent a year as a post-doc at the Oxford Centre for Neuroethics researching the implications of various novel biotechnologies. Owen joined CBmE in August 2015 under the MOH-funded initiative, Clinical Ethics Network + Research Ethics Support (CENTRES). In January 2018 he switched roles to be a Research Assistant Professor under the Science, Health And Policy-Relevant Ethics in Singapore (SHAPES) initiative at CBmE, funded by a grant from the NMRC, before taking up his present role as Assistant Professor in July 2020. |
 Prof Jon Emery | Prof Jon Emery is the Professor of Family Medicine and Director of the recently established Centre for Cancer Prevention and Early Detection at the Lee Kong Chian School of Medicine, Nanyang Technological University. He was previously the Professor of Primary Care Cancer Research at the University of Melbourne where he remains an Honorary Professor. Prof Jon Emery is an internationally recognised leader in primary care cancer research with specific expertise in the development and evaluation of complex interventions including novel cancer diagnostic and screening technologies, clinical translation of genomics, computer decision support systems, models of cancer survivorship, and use of linked healthcare data to study variations in cancer care. Following his medical training at Cambridge and Oxford, he has had a highly successful career in academic primary care, initially at Oxford, where he obtained his DPhil on cancer risk assessment tools, then as a Cancer Research UK Clinician Scientist at Cambridge before taking up a Chair at the University of Western Australia. He moved to the University of Melbourne in 2013 for a Chair linked to the establishment of the Victorian Comprehensive Cancer Centre where he led the creation of one of the largest cancer in primary care research groups in the world. |
 Adj A/Prof Chee Cheng Ean | Adj A/Prof Chee Cheng Ean is the Executive Director of the National University Cancer Institute, Singapore. In this role, she provides leadership and direction, facilitates operations and is responsible for implementing strategic initiatives for NCIS (pronounced N-CIS), which is the only public, academic cancer center in Singapore treating both pediatric and adult cancers in one facility.
|
